Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,609 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (799)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00143559 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | completed | Phase 2 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00152139 | Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 3 | 33 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00186823 |
| Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies |
| completed |
| Phase 3 |
| 57 |
| St. Jude Children's Research HospitalOTHER |
| 1 |
| Jan 29, 2009 |
| clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00815568 | Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) | unknown | Phase 2 | 114 | Samsung Medical CenterOTHER | 1 | Dec 30, 2008 | clinicaltrials |
| NCT00390897 | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia | completed | Phase 4 | 360 | PETHEMA FoundationOTHER | 1 | Nov 27, 2008 | clinicaltrials |
| NCT00487448 | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia(FLAG-IDA) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Nov 19, 2008 | clinicaltrials |
| NCT00488709 | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia(FLAT) | completed | Phase 4 | 47 | PETHEMA FoundationOTHER | 1 | Nov 18, 2008 | clinicaltrials |
| NCT00114764 | Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 84 | AmgenINDUSTRY | 0 | Oct 31, 2008 | clinicaltrials |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 2 | 20 | University of CincinnatiOTHER | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00559221 | FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML | unknown | Phase 2 | 37 | Cooperative Study Group A for HematologyNETWORK | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00001144 | Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia | completed | Phase 2 | 50 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 7, 2008 | clinicaltrials |
| NCT00728520 | Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | unknown | Phase 2 | 40 | Kansas City Veteran Affairs Medical CenterFED | 1 | Aug 6, 2008 | clinicaltrials |
| NCT00700544 | Treatment Outcome in Elderly Patients | completed | Phase 3 | 330 | University Hospital, GrenobleOTHER | 1 | Jun 18, 2008 | clinicaltrials |
| NCT00675870 | Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | unknown | Phase 2 | 65 | NuRx Pharmaceuticals, Inc.INDUSTRY | 1 | May 12, 2008 | clinicaltrials |
| NCT00667927 | Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission | completed | Phase 1 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2008 | clinicaltrials |
| NCT00129168 | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 100 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00233909 | A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 55 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00465933 | Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) | completed | Phase 4 | — | PETHEMA FoundationOTHER | 1 | Mar 31, 2008 | clinicaltrials |
| NCT00001432 | The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies | completed | — | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001748 | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001839 | A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome | completed | Phase 2 | 182 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00363025 | A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. | terminated | Phase 3 | 465 | Acute Leukemia French AssociationOTHER | 1 | Feb 21, 2008 | clinicaltrials |
| NCT00274248 | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia | completed | Phase 1 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00104468 | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 50 | SGX Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 17, 2008 | clinicaltrials |
| NCT00116467 | Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia | completed | Phase 2 | 55 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00041990 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | completed | Phase 2 | 40 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 17, 2007 | clinicaltrials |
| NCT00552825 | Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children | completed | — | 35 | Sheba Medical CenterOTHER_GOV | 1 | Nov 2, 2007 | clinicaltrials |
| NCT00196768 | Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic | unknown | Phase 4 | 30 | German AML Cooperative GroupOTHER | 1 | Oct 23, 2007 | clinicaltrials |
| NCT00529880 | Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML | unknown | Phase 2 | 19 | Cooperative Study Group A for HematologyNETWORK | 1 | Sep 27, 2007 | clinicaltrials |
| NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia(IAPLSG04) | unknown | Phase 2 / Phase 3 | 400 | Christian Medical College, Vellore, IndiaOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00514488 | Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)(CML022) | completed | Phase 3 | — | University of BolognaOTHER | 1 | Aug 10, 2007 | clinicaltrials |
| NCT00514969 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase(CML003) | completed | Phase 2 | — | University of BolognaOTHER | 1 | Aug 10, 2007 | clinicaltrials |
| NCT00510926 | Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase | completed | Phase 2 | 80 | University of BolognaOTHER | 1 | Aug 3, 2007 | clinicaltrials |
| NCT00511121 | Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) | terminated | Phase 2 | 5 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00511303 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | completed | Phase 2 | 200 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00480064 | Lomustine and Intermediate Dose Cytarabine in Older Patients With AML | completed | Phase 3 | 360 | French Innovative Leukemia OrganisationOTHER | 1 | May 30, 2007 | clinicaltrials |
| NCT00126893 | Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia | terminated | Phase 1 | 36 | Celgene CorporationINDUSTRY | 1 | May 15, 2007 | clinicaltrials |
| NCT00146913 | AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year | unknown | Phase 2 | 30 | Hospices Civils de LyonOTHER | 1 | Apr 27, 2007 | clinicaltrials |
| NCT00299780 | Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. | completed | Phase 1 | 12 | Massachusetts General HospitalOTHER | 1 | Apr 24, 2007 | clinicaltrials |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 23, 2007 | clinicaltrials |
| NCT00460447 | Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | University Hospital Carl Gustav CarusOTHER | 1 | Apr 16, 2007 | clinicaltrials |
| NCT00089596 | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | completed | Phase 1 / Phase 2 | 10 | ViaCellINDUSTRY | 1 | Apr 12, 2007 | clinicaltrials |
| NCT00161668 | Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care | completed | — | 500 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Mar 15, 2007 | clinicaltrials |
| NCT00273884 | Amonafide in Combination With Cytarabine in Secondary AML | completed | Phase 2 | 80 | Xanthus Pharmaceuticals, Inc.INDUSTRY | 2 | Feb 19, 2007 | clinicaltrials |
| NCT00329498 | L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes | suspended | Phase 2 | 25 | Samsung Medical CenterOTHER | 1 | Oct 26, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00328237 | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | unknown | Phase 2 | 20 | Colorado Blood Cancer InstituteOTHER | 1 | Jun 26, 2006 | clinicaltrials |
| NCT00327262 | Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase | unknown | Phase 3 | 240 | Central European Leukemia Study GroupOTHER | 1 | Jun 20, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Jan 29, 2009source: clinicaltrials